Home
/
Vertili™ Prenatal

Vertili™ Prenatal w/ DHA & Iodine

Advanced Prenatal Vitamin & Mineral Formula

90 Softgel Capsules | 30-Day Supply

$49.99
Special Offer: Buy 2, Get 1 Free!
Available Soon
$2.99 flat-rate shipping worldwide

Buy two (2) Vertili™ at $49.99 each
($99.98 total + $2.99 shipping) and
receive a 3rd Vertili™ for free!

Thank you; please check
your e-mail!

Vertili™ is a once-daily advanced prenatal vitamin and mineral formula; formulated to cover your vital preconception, pregnancy, and breastfeeding essentials, from head to toe and beyond.

Overview
Ingredients
Usage
Warning
References

Overview

3 capsules once-daily
Complete spectrum of prenatal vitamins & minerals
Supports a healthy pregnancy & fetal development
1000mcg of FolaPure™ (L-Methylfolate)
400mg of UltraDHA™ (TG DHA Omega-3 Oil)

Preconception, pregnancy, and breastfeeding, are some of the most important stages in your life. As you experience the miracle of conceiving, becoming pregnant, and bringing new life into this world, your vitamin, mineral, and nutrient requirements change significantly.

During these stages, key vitamins and minerals play important roles in supporting an enjoyable, healthy and successful pregnancy. Unfortunately, today's demanding lifestyles combined with the added stress of pregnancy, make it difficult for you to provide you and your baby with these prenatal nutrients on a daily basis.

Introducing Vertili™ - an advanced prenatal specially formulated to meet your daily prenatal requirements. Vertili™ is formulated with DHA and an optimal combination of 27 unique prenatal vitamins and minerals; including L-methylfolate.

L-methylfolate is included for the prevention of birth defects and to lower homocysteine levels,^1-9 and is proven to be up to 700% more bioavailable than regular folic acid.¹⁰ L-methylfolate is the active form of folic acid which is not affected by MTHFR genotype variations and can be immediately absorbed by your body.^11-14

DHA is included to support healthy fetal brain and eye development,^15-29 and is proven to increase the IQ of children at 4-years of age.³⁰ In particular, Vertili™ is formulated with Triglyceride (TG) DHA, with TG DHA proven to be up to 70% more bioavailable than regular Ethyl-Ester (EE) DHA.³¹

Vertili™ also includes Iodine for proper thyroid function and brain development,^32-38 non-constipating Iron to support increased blood volume and prevent anemia,^39-43 Vitamin D3 to support calcium absorption and bone development,^44-56 and Vitamin B6 to prevent morning sickness.^57-61

Support your prenatal journey before, during, and after pregnancy, with Vertili™ - the trusted and leading prenatal formulated with 400mg of DHA, and a unique combination 27 prenatal vitamins and minerals; including 1000mcg of L-methylfolate.

Ingredients

Nutritional Facts Panel Available Soon.

Learn about the ingredients in Vertili™:

Usage

As a dietary supplement to support a healthy pregnancy and fetal development, take 3 Vertili™ capsules daily. While it is preferable to take Vertili™ in the morning with or before breakfast, Vertili™ can be taken at anytime during the day.

Warning

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Ingestion of more than 3 grams per day of omega-3 fatty acids has been shown to have potential antithrombotic effects, including an increased bleeding time and International Normalized Ratio (INR). Administration of omega-3 fatty acids should be avoided if you are taking anticoagulant (blood thinner) medication and/or have an inherited or acquired bleeding diathesis.

Folic acid in doses above 0.1mg daily may reverse the hematological manifestations of B12 deficiency, and obscure the detection of B12 deficiency and pernicious anemia.

Vertili™ should always be dispensed under the guidance of a health care provider and the recommended dosage should never be exceeded.

References

Mills, J.L., et al., Homocysteine and neural tube defects. J Nutr, 1996. 126(3): p. 756S-760S.
Mills, J.L., et al., Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet, 1995. 345(8943): p. 149-51.
Lucock, M.D., et al., The methylfolate axis in neural tube defects: in vitro characterisation and clinical investigation. Biochem Med Metab Biol, 1994. 52(2): p. 101-14.
Blom, H.J., et al., Neural tube defects and folate: case far from closed. Nat Rev Neurosci, 2006. 7(9): p. 724-31.
Wilson, R.D., et al., Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can, 2007. 29(12): p. 1003-26.
Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet, 1991. 338(8760): p. 131-7.
Czeizel, A.E. and I. Dudas, Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med, 1992. 327(26): p. 1832-5.
Czeizel, A.E., The primary prevention of birth defects: Multivitamins or folic acid? Int J Med Sci, 2004. 1(1): p. 50-61.
Vergel, R.G., et al., Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn, 1990. 10(3): p. 149-52.
Willems, F.F., et al., Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol, 2004. 141(5): p. 825-30.
Klerk, M., et al., MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA, 2002. 288(16): p. 2023-31.
Blom, H.J., et al., Neural tube defects and folate: case far from closed. Nat Rev Neurosci, 2006. 7(9): p. 724-31.
Lamers, Y., et al., Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr, 2006. 84(1): p. 156-61.
Jacques, P.F., et al., Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 1996. 93(1): p. 7-9.
Birch, E.E., et al., A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. Am J Clin Nutr, 2002. 75(3): p. 570-80.
Birch, E.E., et al., A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. Am J Clin Nutr, 2002. 75(3): p. 570-80.
Makrides, M., et al., Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet, 1995. 345(8963): p. 1463-8.
Birch, E., et al., Breast-feeding and optimal visual development. J Pediatr Ophthalmol Strabismus, 1993. 30(1): p. 33-8.
Innis, S.M., et al., Development of visual acuity in relation to plasma and erythrocyte omega-6 and omega-3 fatty acids in healthy term gestation infants. Am J Clin Nutr, 1994. 60(3): p. 347-52.
Birch, E.E., et al., Dietary essential fatty acid supply and visual acuity development. Invest Ophthalmol Vis Sci, 1992. 33(11): p. 3242-53.
Futterman, S., J.L. Downer, and A. Hendrickson, Effect of essential fatty acid deficiency on the fatty acid composition, morphology, and electroretinographic response of the retina. Invest Ophthalmol, 1971. 10(2): p. 151-6.
Makrides, M., et al., Erythrocyte docosahexaenoic acid correlates with the visual response of healthy, term infants. Pediatr Res, 1993. 33(4 Pt 1): p. 425-7.
Horrocks, L.A. and Y.K. Yeo, Health benefits of docosahexaenoic acid (DHA). Pharmacol Res, 1999. 40(3): p. 211-25.
Innis, S.M., et al., Visual acuity and blood lipids in term infants fed human milk or formulae. Lipids, 1997. 32(1): p. 63-72.
Jorgensen, M.H., et al., Visual acuity and erythrocyte docosahexaenoic acid status in breast-fed and formula-fed term infants during the first four months of life. Lipids, 1996. 31(1): p. 99-105.
Carlson, S.E., et al., Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res, 1996. 39(5): p. 882-8.
Birch, E.E., et al., Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res, 1998. 44(2): p. 201-9.
Courage, M.L., et al., Visual acuity development and fatty acid composition of erythrocytes in full-term infants fed breast milk, commercial formula, or evaporated milk. J Dev Behav Pediatr, 1998. 19(1): p. 9-17.
Hoffman, D.R., et al., Visual function in breast-fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: a randomized clinical trial. J Pediatr, 2003. 142(6): p. 669-77.
Helland, I.B., et al., Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics, 2003. 111(1): p. e39-44.
Dyerberg, J., et al., Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids, 2010. 83(3): p. 137-41.
Glinoer, D., Clinical and biological consequences of iodine deficiency during pregnancy. Endocr Dev, 2007. 10: p. 62-85.
Velasco, I., et al., Effect of iodine prophylaxis during pregnancy on neurocognitive development of children during the first two years of life. J Clin Endocrinol Metab, 2009. 94(9): p. 3234-41.
O'Donnell, K.J., et al., Effects of iodine supplementation during pregnancy on child growth and development at school age. Dev Med Child Neurol, 2002. 44(2): p. 76-81.
Glinoer, D., The importance of iodine nutrition during pregnancy. Public Health Nutr, 2007. 10(12A): p. 1542-6.
Moscicka, A. and J. Gadzinowski, [The influence of iodine deficiency during pregnancy of fetal and neonatal development]. Ginekol Pol, 2001. 72(11): p. 908-16.
de Escobar, G.M., M.J. Obregon, and F.E. del Rey, Iodine deficiency and brain development in the first half of pregnancy. Public Health Nutr, 2007. 10(12A): p. 1554-70.
Melse-Boonstra, A. and N. Jaiswal, Iodine deficiency in pregnancy, infancy and childhood and its consequences for brain development. Best Pract Res Clin Endocrinol Metab, 2010. 24(1): p. 29-38.
Huebers, H.A., et al., Absorption of carbonyl iron. J Lab Clin Med, 1986. 108(5): p. 473-8.
Devasthali, S.D., et al., Bioavailability of carbonyl iron: a randomized, double-blind study. Eur J Haematol, 1991. 46(5): p. 272-8.
Gordeuk, V.R., et al., Carbonyl iron therapy for iron deficiency anemia. Blood, 1986. 67(3): p. 745-52.
Gordeuk, V.R., et al., High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr, 1987. 46(6): p. 1029-34.
Lynch, S.R. and R.J. Stoltzfus, Iron and ascorbic Acid: proposed fortification levels and recommended iron compounds. J Nutr, 2003. 133(9): p. 2978S-84S.
Marie, P.J., et al., Bone changes due to pregnancy and lactation: influence of vitamin D status. Am J Physiol, 1986. 251(4 Pt 1): p. E400-6.
Haliloglu, B., et al., Bone turnover and maternal 25(OH) vitamin D3 levels during pregnancy and the postpartum period: should routine vitamin D supplementation be increased in pregnant women? Eur J Obstet Gynecol Reprod Biol, 2011. 158(1): p. 24-7.
Trivedi, D.P., R. Doll, and K.T. Khaw, Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ, 2003. 326(7387): p. 469.
Wang, J., et al., [Effects of calcium and vitamin D supplementation on bone specific alkaline during pregnancy lactation and infant]. Wei Sheng Yan Jiu, 2009. 38(2): p. 193-5.
Lanham-New, S.A., Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment. Proc Nutr Soc, 2008. 67(2): p. 163-76.
Heaney, R.P., Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr, 2003. 78(5): p. 912-9.
Hollis, B.W. and C.L. Wagner, Nutritional vitamin D status during pregnancy: reasons for concern. CMAJ, 2006. 174(9): p. 1287-90.
LeBoff, M.S., et al., Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA, 1999. 281(16): p. 1505-11.
Holick, M.F., Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging, 2007. 24(12): p. 1017-29.
Dawson-Hughes, B., et al., Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr, 1995. 61(5): p. 1140-5.
Chapuy, M.C., et al., Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med, 1992. 327(23): p. 1637-42.
Reichrath, J. and K. Querings, Vitamin D deficiency during pregnancy: a risk factor not only for fetal growth and bone metabolism but also for correct development of the fetal immune system? Am J Clin Nutr, 2005. 81(5): p. 1177; author reply 1177-8.
Chaudhuri, A., Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses, 2005. 64(3): p. 608-18.
Ensiyeh, J. and M.A. Sakineh, Comparing ginger and vitamin B6 for the treatment of nausea and vomiting in pregnancy: a randomised controlled trial. Midwifery, 2009. 25(6): p. 649-53.
Chittumma, P., K. Kaewkiattikun, and B. Wiriyasiriwach, Comparison of the effectiveness of ginger and vitamin B6 for treatment of nausea and vomiting in early pregnancy: a randomized double-blind controlled trial. J Med Assoc Thai, 2007. 90(1): p. 15-20.
Schuster, K., et al., Morning sickness and vitamin B6 status of pregnant women. Hum Nutr Clin Nutr, 1985. 39(1): p. 75-9.
Sripramote, M. and N. Lekhyananda, A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. J Med Assoc Thai, 2003. 86(9): p. 846-53.
Sahakian, V., et al., Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol, 1991. 78(1): p. 33-6.